Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.

The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem ...

I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to ...

The following is a summary of “Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations,” published in the February 2025 issue of the International Journal of ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

In honor of a W.F. West High School student who is battling a rare bone marrow disorder and a Chehalis woman who fought ...

President Trump’s popularity is skyrocketing, which, of course, must be driving the many afflicted with Trump Derangement Syndrome even battier than they already were. The president is not only keepin ...

Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS) drug candidate imetelstat. A briefing document (PDF ...

myelodyplastic syndromes (MDS), having met primary and key secondary endpoints. The COMMANDS study (NCT03682536) - a phase 3 open-label, randomised trial to evaluate the efficacy and safety of ...